Cobenfy: The First New Schizophrenia Drug in Decades
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
Kraynak requests federal judge's recusal
The former Dr. Raymond Kraynak who is still fighting to overturn his 15-year federal sentence wants the federal judge who presided over his trial to recuse himself from the appeal process. Kraynak, ...
Business Wire3 天
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
Kelly on MSN6 天
Is Prison A Deterrent For Drug Crimes?
Unsplash - CC0 License The idea that prison is a deterrent goes back hundreds of years. European jails would take peop ...
JD Supra6 天
CMS Releases Final Rule on the Medicaid Drug Rebate Program
The Centers for Medicare & Medicaid Services (CMS) on Sept. 20, 2024, released the Misclassification of Drugs, Program Administration and ...
The American Journal of Managed Care6 天
New FTC Lawsuit Against PBMs Has Broad Implications for Pharmaceuticals, Ted Okon Says
Ted Okon, MBA, executive director of the Community Oncology Alliance, spoke with The American Journal of Managed Care® about how the Federal Trade Commission's (FTC) lawsuit against pharmacy benefit ...